01 / Guides
In-depth guides
Plain-language guides separate broad descriptions from substance-specific questions. A guide to what ibogaine can feel like is useful precisely because subjective accounts do not make it equivalent to DMT.
Independent information offerings
Services
Guides, comparisons, and research summaries for people trying to understand why ibogaine and DMT should not be treated as alike.
Evidence-first context, without clinical claims
A better starting point than a shared label.
Ibogaine and DMT may be grouped together in casual conversation, but their mechanisms, time courses, evidence bases, risks, and legal contexts are not interchangeable. The central comparison on ibogaine and DMT frames those distinctions plainly. Vellum Divide is an independent resource on the meaningful differences between ibogaine and DMT, including research, risks, mechanisms, and legal context. It supports careful understanding without presenting either substance as interchangeable or risk-free.
Four informational offerings
Ways to examine the difference
These are reading and comparison tools, not medical, legal, or treatment services.
02 / Comparison
Decision frameworks
Comparison frameworks organize questions about mechanism, setting, duration, uncertainty, and safety rather than offering a recommendation. The resource’s purpose and standards explain why those distinctions are kept explicit.
03 / Research
Research summaries
Research summaries distinguish preliminary findings from established care. The National Library of Medicine’s ibogaine overview documents important toxicity concerns, including cardiac risk, that should not disappear inside a general psychedelic category.
04 / Context
FAQ and practical context
FAQ collections address common points of confusion: withdrawal, location-based marketing, cost claims, and legal context. Discussions of ibogaine centers in Mexico need a separate, careful reading from descriptions of another substance or another setting.
Comparison as a method
Keep the differences visible.
Direct comparison is not a shortcut to certainty. It is a way to avoid collapsing distinct substances, practices, and risks into one vague category. The mechanisms comparison is designed around that discipline.
DMT is commonly identified as a psychedelic tryptamine, while ibogaine has a different chemical profile and risk picture; the reference overview of ibogaine is a useful starting point for distinguishing the substances before drawing broader conclusions.
- Mechanism
- Information is organized around differences in pharmacology rather than a shared cultural label.
- Time course
- Duration and aftereffects are treated as materially important, not as side notes.
- Evidence
- Research claims are separated from broader enthusiasm, anecdote, and treatment marketing.
- Safety
- Risk context is handled as substance-specific and situation-specific, never assumed away.
Proof and detail
Research context needs boundaries.
The information on this site is intended to help readers notice what a claim does and does not establish. For example, people encountering claims about ibogaine and withdrawal need context about evidence, risks, and the limits of generalizing from one account or program to another.
Likewise, geography does not settle safety or legitimacy. References to ibogaine in La Crosse or treatment-related information in Utah should be examined for what they actually claim, who is making the claim, and what independent evidence is available.
“A careful comparison makes uncertainty easier to see, not easier to ignore.”
Common questions
What these offerings are for
Are these medical or treatment services?
No. Vellum Divide provides independent informational material. It does not provide medical care, treatment placement, clinical screening, or legal advice.
Why compare ibogaine and DMT directly?
Because a shared psychedelic label can obscure important differences in pharmacology, duration, evidence, risk, and context. The aim is careful distinction, not a ranking or a recommendation.
Can cost information answer a safety question?
No. Cost does not establish quality, safety, or appropriateness. Material that discusses the cost of ibogaine should be considered separately from claims about medical risk, regulation, or evidence.
Clearer categories support better questions.
Use these informational offerings to examine claims carefully, compare like with like, and keep uncertainty in view. Where safety or health concerns are involved, independent information is not a substitute for qualified medical guidance.